Previous close | 1.5500 |
Open | 1.5500 |
Bid | 1.6000 |
Ask | 2.4500 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 1.5500 - 1.5500 |
Contract range | N/A |
Volume | |
Open interest | 13 |
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV)HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial NEW YORK and VIENNA, July 01, 2024 (GL
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months
Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA’s Executive Team will host an investor call on